Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
16
Today In Oncology
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
What Constitutes Clinical Expertise in an AI-Enabled Era
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo